Among them, PI3K/AKT/mTOR and MAPK pathways have been widely proved to be the core targets of CTD against tumor metastasis, and CTD, as a multi-targeted anticancer agent, has demonstrated its unique advantages in inhibiting tumor growth, metastasis, and synergistic radiotherapy. This evidence concerns the gene AKT1 and neoplasm.